Center for International Blood and Marrow Transplant Research (CIBMTR) - Consent for Participation and Donation of Blood Samples
Patients undergoing marrow transplantation from an unrelated donor are being asked to provide one blood sample. one blood sample will be collected prior to the transplant. The blood sample will be frozen and used later in research which will compare the recipients' cells with the pertinent donors' cells. Patients will not be identified by name and identities will be kept confidential.
at this center, ten milliliters of blood will be taken from those who have been selected as a matched related donor for the recipient through HLa typing. The donor samples will be collected either prior to or after the HSC collection. The only donors who will be consented and whose blood will be collected will be related donors because this center is not an unrelated donor center.
in cases where donor or recipient samples are unavailable, samples may be taken from any material that may yield Dna, for example, red cell pellets, extracted Dna, dried blood on filter paper, viable cells and any other testable material.
6.3.1 This study has two protocols: the Repository protocol which is attached and the Research Database Protocol, which i will add to the [Quote]supporting documents[Quote].
Males or females 22 years of age or younger undergoing a HC transplantation (includes cells collected from peripheral blood, bone marrow or cord blood) or any recipient of cellular therapy and who have signed a written informed consent will be eligible to participate in this research study. Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the NMDP Research Sample Repository. This includes adults with and without decision making capacity and children. Eligible individuals may have received support care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.
Related donors are deemed suitable after confirmatory tissue typing has been completed and a genetic match is identified.